Athersys, Inc. (ATHX): Price and Financial Metrics


Athersys, Inc. (ATHX): $1.88

-0.13 (-6.47%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ATHX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 485

in industry

ATHX Stock Summary

  • The ratio of debt to operating expenses for Athersys Inc is higher than it is for about just 0.48% of US stocks.
  • ATHX's price/sales ratio is 869.53; that's higher than the P/S ratio of 99.14% of US stocks.
  • Revenue growth over the past 12 months for Athersys Inc comes in at -93.34%, a number that bests just 1.2% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Athersys Inc are CRNX, FIXX, BBIO, INO, and NTLA.
  • ATHX's SEC filings can be seen here. And to visit Athersys Inc's official web site, go to www.athersys.com.

ATHX Stock Price Chart Interactive Chart >

Price chart for ATHX

ATHX Price/Volume Stats

Current price $1.88 52-week high $4.38
Prev. close $2.01 52-week low $1.13
Day low $1.88 Volume 3,547,155
Day high $2.08 Avg. volume 3,343,521
50-day MA $2.15 Dividend yield N/A
200-day MA $2.25 Market Cap 371.68M

Athersys, Inc. (ATHX) Company Bio


Athersys, Inc. focuses on the research and development activities in the field of regenerative medicine. The company was founded in 1995 and is based in Cleveland, Ohio.


ATHX Latest News Stream


Event/Time News Detail
Loading, please wait...

ATHX Latest Social Stream


Loading social stream, please wait...

View Full ATHX Social Stream

Latest ATHX News From Around the Web

Below are the latest news stories about Athersys Inc that investors may wish to consider to help them evaluate ATHX as an investment opportunity.

Athersys to Host Year-End 2020 Financial Results Call

Athersys will host the year-end 2020 financial results call on March 25th.

Yahoo | March 2, 2021

Athersys Announces CEO Transition

CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX #Athersys--Gil Van Bokkelen to Step Down as Chairman and CEO of Athersys

Business Wire | February 16, 2021

Athersys Announces Cooperation Agreement With HEALIOS K.K.

Athersys and Healios commit to work in good faith to finalize negotiations important to successful commercialization in Japan.

Yahoo | February 16, 2021

Longeveron Seeks $25 Million IPO For Anti-Aging Efforts

Quick Take Longeveron (LGVN) has filed to raise $25 million in an IPO of its Class A common stock, according to an S-1 registration statement. The firm is a clinical stage firm is developing treatment candidates for various aging conditions. LGVN is thinly capitalized and pursuing an ultra-high-risk effort for...

Donovan Jones on Seeking Alpha | February 5, 2021

Update On Athersys - Trying To Read Between The Lines

There is a very fascinating confluence of circumstances that have come together over the last few months surrounding the shares of stem cell therapeutics company, Athersys Inc. (ATHX). I’ve held the shares for longer than I want to admit and I recently was informed that, in the new language of...

Wall Street Titan on Seeking Alpha | February 3, 2021

Read More 'ATHX' Stories Here

ATHX Price Returns

1-mo -22.95%
3-mo 9.30%
6-mo -4.57%
1-year 54.10%
3-year 38.24%
5-year 5.62%
YTD 7.43%
2020 42.28%
2019 -14.58%
2018 -20.44%
2017 18.30%
2016 48.54%

Continue Researching ATHX

Here are a few links from around the web to help you further your research on Athersys Inc's stock as an investment opportunity:

Athersys Inc (ATHX) Stock Price | Nasdaq
Athersys Inc (ATHX) Stock Quote, History and News - Yahoo Finance
Athersys Inc (ATHX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8465 seconds.